Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104

• Juliana Benito,

  Affiliation Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Yuexi Shi,

  Affiliation Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Barbara Szymanska,

  Affiliation C25 Lowy Cancer Research Centre, Children's Cancer Institute Australia for Medical Research, University of New South Wales, Randwick, New South Wales, Australia

  ⨯
• Hernan Carol,

  Affiliation C25 Lowy Cancer Research Centre, Children's Cancer Institute Australia for Medical Research, University of New South Wales, Randwick, New South Wales, Australia

  ⨯
• Ingrid Boehm,

  Affiliation C25 Lowy Cancer Research Centre, Children's Cancer Institute Australia for Medical Research, University of New South Wales, Randwick, New South Wales, Australia

  ⨯
• Hongbo Lu,

  Affiliation Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Sergej Konoplev,

  Affiliation Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Wendy Fang,

  Affiliation Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Patrick A. Zweidler-McKay,

  Affiliation Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Dario Campana,

  Affiliation St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America

  ⨯
• Gautam Borthakur,

  Affiliation Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Carlos Bueso-Ramos,

  Affiliation Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Elizabeth Shpall,

  Affiliation Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Deborah A. Thomas,

  Affiliation Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Craig T. Jordan,

  Affiliation School of Medicine and Dentistry, University of Rochester, Rochester, New York, United States of America

  ⨯
• Hagop Kantarjian,

  Affiliation Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• William R. Wilson,

  Affiliation Auckland Cancer Society Research Center, The University of Auckland, Auckland, New Zealand

  ⨯
• Richard Lock,

  Affiliation Auckland Cancer Society Research Center, The University of Auckland, Auckland, New Zealand

  ⨯
• Michael Andreeff,

  Affiliations Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
•  [ ... ],
• Marina Konopleva

  * E-mail: mkonople@mdanderson.org

  Affiliations Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• [ view all ]
• [ view less ]